Hepatology
Portopulmonary hypertension: current developments and future perspectives.
21 Nov, 2022 | 14:20h | UTCPortopulmonary hypertension: Current developments and future perspectives – Liver Research
Related: Pulmonary complications in liver disease – Intensive Care Medicine (free)
Related Reviews:
Pulmonary complications of hepatic diseases – World Journal of Gastroenterology
Phase 2b RCT | Efficacy and safety of Bepirovirsen in chronic Hepatitis B infection.
11 Nov, 2022 | 13:44h | UTCEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hep B virus (HBV) messenger RNAs, resulted in sustained loss of hep B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection. #TLM22 #LiverTwitter https://t.co/krJcMEDhIX pic.twitter.com/SistuAocZO
— NEJM (@NEJM) November 8, 2022
Retrospective Cohort Study | Perinatal outcomes associated with ICP in twin pregnancies were worse than singletons.
11 Nov, 2022 | 13:36h | UTC
M-A | Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis.
8 Nov, 2022 | 11:58h | UTC
Review | Determining prognosis of alcoholic liver disease and alcoholic hepatitis.
4 Nov, 2022 | 13:17h | UTC
ERAS Guidelines for perioperative care for liver surgery.
1 Nov, 2022 | 12:16h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Review | Management of NAFLD in primary care settings.
27 Oct, 2022 | 12:24h | UTCManagement of NAFLD in primary care settings – Liver International
Related:
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
Commentary on Twitter
Opportunities of assessment and treatment of #NAFLD in primary care settings
✍️ @VWSWong @DrJavierCrespo @JVLazarus #livertwitter #liverreviews #NASH pic.twitter.com/5SLqNvafAm
— Liver International (@LiverInt) October 23, 2022
AHA Scientific Statement | Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates.
24 Oct, 2022 | 14:11h | UTCTop Things to Know: Emerging Evidence on Coronary Heart Disease (CHD) Screening in Kidney and Liver Transplantation Candidates – American Heart Association
Case-control study | Post-paracentesis ascitic fluid leak in patients with cirrhosis of liver and its management.
21 Oct, 2022 | 12:57h | UTC
M-A of RCT | Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis.
20 Oct, 2022 | 12:25h | UTCCarvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis – Journal of Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
#Carvedilol
➡️non-selective #βblocker
✅associated with reduced risk of decompensating events
➡️improved survival in patients with #cirrhosis & #portalhypertensionRead it here?https://t.co/yy8DIJBhfL#LiverTwitter pic.twitter.com/XxmrB7gff8
— Journal of Hepatology (@JHepatology) October 13, 2022
Choosing Wisely | Top five list of procedures to avoid in the treatment of viral hepatitis.
7 Oct, 2022 | 14:22h | UTCSee complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Baveno VII – Renewing consensus in portal hypertension.
7 Oct, 2022 | 14:17h | UTCBaveno VII – Renewing consensus in portal hypertension – Journal of Hepatology
RCT | Trientine tetrahydrochloride noninferior to penicillamine for maintenance therapy in Wilson disease.
7 Oct, 2022 | 14:10h | UTCTrientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Schilsky et al – Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial https://t.co/OS0kh2EkM0#livertwitter #wilsonsdisease #wilsondisease pic.twitter.com/Grizm2uN7F
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 30, 2022
Review | Alcohol and acute-on-chronic liver failure.
4 Oct, 2022 | 14:33h | UTCAlcohol and Acute-on-Chronic Liver Failure – Journal of Clinical and Experimental Hepatology
Related:
Acute-on-Chronic Liver Failure Clinical Guidelines – American Journal of Gastroenterology
Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU
Supplement | The role of liver transplantation in acute-on-chronic liver failure.
Review | Acute kidney injury in patients with liver disease.
3 Oct, 2022 | 13:56h | UTC
Commentary on Twitter
AKI is commonly encountered in patients with decompensated cirrhosis, and it is associated with unfavorable outcomes. This article discusses tailoring management of AKI in patients with liver disease to the specific underlying etiology https://t.co/UVEeYBL8ff@VelezNephHepato pic.twitter.com/V5J8hBQyuw
— CJASN (@CJASN) September 27, 2022
Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients.
28 Sep, 2022 | 13:37h | UTC
Practice Guidance | A multidisciplinary approach to the diagnosis and management of Wilson Disease.
27 Sep, 2022 | 13:13h | UTC
Review | Adrenal insufficiency in cirrhosis.
22 Sep, 2022 | 12:59h | UTCAdrenal Insufficiency in Cirrhosis – Journal of the Endocrine Society
Nutrition assessment and management in patients with cirrhosis and cognitive impairment: a comprehensive review of literature.
19 Sep, 2022 | 12:29h | UTCCommentary: Review Outlines Nutrition Assessment, Management in Patients With Cirrhosis – AJMC
Update | Management of hepatorenal syndrome in liver cirrhosis.
19 Sep, 2022 | 12:27h | UTC
German guidelines on non-alcoholic fatty liver disease.
15 Sep, 2022 | 13:07h | UTCRelated:
Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports
Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts.
13 Sep, 2022 | 13:13h | UTC
Commentary on Twitter
Artificial liver support
? albumin dialysis
? acute failure
? decompensated cirrhosis/acute‑on‑chronic failure
? refractory pruritus
? hypoxic injury
? post‑hepatectomy failure
? graft failure post #Tx
? drug overdose
? technique/safety#FOAMcc
? https://t.co/d841FcTHEd pic.twitter.com/gO79gLs60a— Intensive Care Medicine (@yourICM) September 7, 2022
M-A | Combination therapy with rifaximin and lactulose in hepatic encephalopathy.
11 Sep, 2022 | 22:33h | UTCCommentary: Rifaximin Plus Lactulose Linked to Greater Effectiveness, Decreased Mortality in HE – AJMC
Nonalcoholic fatty liver disease: review of management for primary care providers.
5 Sep, 2022 | 14:18h | UTC
Systematic Review | Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
5 Sep, 2022 | 14:13h | UTC